Harmony Bio在新的Wakix专利诉讼后飙升

2026-04-22 01:23

Shares of Harmony Biosciences (HRMY) climbed on Tuesday after Mizuho issued bullish remarks on the stock, citing a new patent litigation filed by the company to fight generics targeting its sleep disorder therapy, Wakix.
Analyst Graig Suvannavejh noted that the lawsuit filed on April 20 against privately held AET Pharma and its commercial partner Sandoz (SDZNY) (SDZXF) alleges infringement of a '920 patent covering Wakix, Harmony’s (HRMY) only approved product.
The development is a “significant positive” for the company, Suvannavejh argued, noting that it will help Harmony (HRMY) remove a major overhang that implied a potential market entry of Wakix generics well before 2030.
“Given this most recent legal salvo from HRMY, we believe HRMY's Wakix franchise should now be viewed as being protected and fully intact until 2030,” the analyst wrote, reiterating his Outperform rating and $50 target on the stock.

More on Harmony Biosciences Holdings, Inc.